samedan logo
 
 
spacer
home > pmps > spring 2004 > achieve controlled release and increased bioavailability of pharmaceutical compounds through spray drying
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Achieve Controlled Release and Increased Bioavailability of Pharmaceutical Compounds Through Spray Drying

The recent interest in highly potent but poorly soluble pharmaceutical compounds has made controlled release and enhanced bioavailability of critical importance for many pharmaceutical dosage forms. This article describes spray drying techniques for manufacturing of products achieving controlled release and/or enhanced bioavailability. Four main categories of products are investigated, nano particles, microencapsulation, solid amorphous dispersions and dry emulsions.

Spray Drying

Spray drying is a very fast method of drying due to the large product surface area and high heat transfer coefficients available. The large surface area also allows for drying at a moderate to low temperature. These properties make spray drying feasible for heat sensitive materials. Rapid drying, and consequently fast stabilisation of feed material, makes spray drying ideally suited for encapsulation and producing dry emulsions or amorphous material. Particle engineering possibilities also include powder performance characteristics, such as aerodynamic particle size, geometric particle size, particle size distribution and powder flow properties.

Nano Particles

Spray drying of nano particles involves drying a suspension of nano particles in a suitable liquid, for example water. By spray drying, the primary particle size can be preserved and at the same time new desirable powder properties can be achieved. For example, powder with good flow properties and reduced tendency to produce air born dust or low aerodynamic particle size, combined with good powder flow properties.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
2
     

There are no comments in regards to this article.

spacer
By Henrik Schwartzbach, Pharma Division Process Technologist at Niro A/S

Henrik Schwartzbach joined Niro A/S in 1992, working in R&D and process optimisation. He has detailed and in-depth knowledge of cutting-edge pharmaceutical spray drying. As the Niro A/S Pharma Division Process Technologist, Henrik is deeply involved in setting the industry standards for pharmaceutical spray drying.
spacer
Henrik Schwartzbach
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement